These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 14750218)

  • 1. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Pan T; Le W; Jankovic J
    Neurology; 2004 Jan; 62(2):343; author reply 343-4. PubMed ID: 14750218
    [No Abstract]   [Full Text] [Related]  

  • 2. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.
    Ahlskog JE; Maraganore DM; Uitti RJ; Uhl GR
    JAMA; 2002 Jul; 288(3):311; author reply 312-3. PubMed ID: 12117385
    [No Abstract]   [Full Text] [Related]  

  • 4. Do dopamine agonists or levodopa modify Parkinson's disease progression?
    Marek K; Jennings D; Seibyl J
    Eur J Neurol; 2002 Nov; 9 Suppl 3():15-22. PubMed ID: 12464117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 6. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Montgomery EB
    Neurology; 2004 Jan; 62(2):343; author reply 343-5. PubMed ID: 14745094
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationale for dopamine agonist use as monotherapy in Parkinson's disease.
    Schwarz J
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S27-33. PubMed ID: 15180135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Ahlskog JE
    Neurology; 2003 Feb; 60(3):381-9. PubMed ID: 12580184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
    MacMahon DG
    Age Ageing; 2003 May; 32(3):244-5. PubMed ID: 12720606
    [No Abstract]   [Full Text] [Related]  

  • 11. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 12. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 13. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.
    Morrish PK
    JAMA; 2002 Jul; 288(3):312; author reply 312-3. PubMed ID: 12117387
    [No Abstract]   [Full Text] [Related]  

  • 15. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.
    Albin RL; Nichols TE; Frey KA
    JAMA; 2002 Jul; 288(3):311-2; author reply 312-3. PubMed ID: 12117386
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP; Piercey MF
    J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Several classes of new drugs emerging for Parkinson disease.
    Phillips P
    JAMA; 1999 Sep; 282(10):929-31. PubMed ID: 10485664
    [No Abstract]   [Full Text] [Related]  

  • 19. DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S93-7. PubMed ID: 12211148
    [No Abstract]   [Full Text] [Related]  

  • 20. Initial agonist treatment of Parkinson disease: a critique.
    Albin RL; Frey KA
    Neurology; 2003 Feb; 60(3):390-4. PubMed ID: 12580185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.